Skip to content

NASDAQ · mid · thesis board

ZLAB Zai Lab

Oncology ADC and licensed portfolio

View race

Thesis

Editorial summary — not a primary filing

China-plus-global oncology pipeline including next ADCs.

Next gate

2027-02-28EstimatedPh2 readout

ADC early data

199 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~7 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~415d)100%
Days to gate (199d)48%
Show math

$750M cash ÷ $55M/mo burn ≈ 415 days. Source: curated SEC quarter figures.

Cash $750M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokMRKPh3okDAWNPh2ok

Risks

  • Geopolitical
  • Partner economics
  • Competitive ADCs
  • Burn

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06105671as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01